<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2019</study_start_year><condition>Colorectal Neoplasms</condition><condition>Metastatic Colorectal Cancer (mCRC)</condition><disease>Colorectal Neoplasms</disease><disease>Metastatic Colorectal Cancer (mcrc)</disease><study_type>Observational</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2735927</full_dataset_link><location>United States</location><study_start_month>1</study_start_month><keyword>MCRC</keyword><keyword>Nivolumab</keyword><keyword>Checkmate-142</keyword><repository>ECRIN MDR</repository><study_status>Completed</study_status></additional><is_claimable>false</is_claimable><name>A Study of Overall Survival in Participants With Metastatic Colorectal Cancer (mCRC)</name><description>The purpose of this study is to estimate the overall survival (OS) for US participants diagnosed with metastatic colorectal cancer (mCRC) by using Flatiron Health’s individual patient level data.</description><dates><creation>2019-01-15</creation></dates><accession>2735927</accession><cross_references><ClinicalTrials___gov>NCT05420909</ClinicalTrials___gov></cross_references></HashMap>